Oral Anti Diabetic Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Global Oral Anti Diabetic Drugs Market is Segmented into Drugs (Biguanides (Metformin), Alpha-glucosidase inhibitors, Dopamine-D2 receptor agonists (Bromocriptin (Cycloset)), Sodium-glucose Cotransport-2 (SGLT-2) inhibitor (Invokana (Canagliflozin), Jardiance (Empagliflozin), Farxiga/Forxiga (Dapagliflozin), and Suglat (Ipragliflozin)), Dipeptidyl Peptidase-4 (DPP-4) Inhibitors (Januvia (Sitagliptin), Onglyza (Saxagliptin), Tradjenta (Linagliptin), Vipidia/Nesina (Alogliptin), and Galvus (Vildagliptin)), Sulfonylureas, and Meglitinides), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America). The market provides the value (in USD million) and volume (in units million) for the above segments.

Oral Anti Diabetic Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Oral Anti Diabetic Drugs Market Size

Oral Anti-Diabetic Drugs Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Market Size (2025) USD 48.77 Billion
Market Size (2030) USD 59.83 Billion
CAGR (2025 - 2030) 4.17 %
Fastest Growing Market Asia-Pacific
Largest Market Asia-Pacific

Major Players

Oral Anti-Diabetic Drugs Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Oral Anti-Diabetic Drugs Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Oral Anti Diabetic Drugs Market Analysis

The Oral Anti-Diabetic Drugs Market size is estimated at USD 48.77 billion in 2025, and is expected to reach USD 59.83 billion by 2030, at a CAGR of 4.17% during the forecast period (2025-2030).

The market is estimated to reach a value of more than USD 52 billion by 2027.

The COVID-19 pandemic has had a substantial impact on the oral anti-diabetic drugs market. The prevalence of diabetes in people hospitalized with COVID-19 infection and the recognition that improved glycemic control might improve outcomes and reduce the length of stay in patients with SARS-CoV-2 have underlined the importance of the oral anti-diabetic drugs market. People with diabetes have a weaker immune system, the COVID-19 complication aggravates the condition, and the immune system gets weaker very fast. Diabetes and uncontrolled hyperglycemia are risk factors for poor outcomes in patients with COVID-19 including an increased risk of severe illness or death. Thus, the COVID-19 outbreak increased the oral anti-diabetic drugs market's growth globally.

According to International Diabetes Federation (IDF), the adult diabetes population in 2021 is approximately 537 million, and this number is going to increase by 643 million in 2030. The rate of newly diagnosed cases of Type 1 and Type 2 diabetes is seen to increase, mainly due to obesity, unhealthy diet, and physical inactivity. The rapidly increasing incidence and prevalence of diabetic patients and healthcare expenditure worldwide are indications of the increasing usage of anti-diabetic drugs. Technological advancements and innovations have increased over the period leading to several modifications either in the drugs or the formulations being developed.

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.

Oral Anti Diabetic Drugs Industry Overview

The oral anti-diabetes drug market is moderately fragmented, with major manufacturers like Eli Lilly, AstraZeneca, Sanofi, Janssen Pharmaceuticals, etc., having a global market presence. In contrast, the remaining manufacturers are confined to the other local or regional markets.

Oral Anti Diabetic Drugs Market Leaders

  1. Eli Lilly and Company

  2. Astellas Pharma Inc.

  3. Sanofi S.A.

  4. Janssen Pharmaceuticals

  5. AstraZeneca

  6. *Disclaimer: Major Players sorted in no particular order
Oral Anti-Diabetic Drugs Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Oral Anti Diabetic Drugs Market News

  • July 2022: Glenmark Pharmaceuticals Limited announced that it had launched sitagliptin and its Fixed Dose Combinations (FDCs) for adults with Type 2 diabetes in India. Glenmark introduced 8 different combinations of sitagliptin-based drugs under the brand name SITAZIT and its variants at an affordable price.
  • March 2022: Oramed announced ORMD-0801 (a new molecule) is being evaluated in two pivotal Phase 3 trials and can be the first oral insulin capsule with the most convenient and safest way to deliver insulin therapy. This drug is expected to be a game-changer in the insulin and oral anti-diabetes drugs markets. Oramed is also developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule (ORMD-0901).

Oral Anti Diabetic Drugs Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
  • 4.3 Market Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION

  • 5.1 Drugs
    • 5.1.1 Biguanides
    • 5.1.1.1 Metformin
    • 5.1.2 Alpha-glucosidase inhibitors
    • 5.1.2.1 Alpha-glucosidase Inhibitors
    • 5.1.3 Dopamine -D2 Receptor Agonist
    • 5.1.3.1 Bromocriptin (Cycloset)
    • 5.1.4 Sodium-glucose Cotransport -2 (SGLT-2) inhibitor
    • 5.1.4.1 Invokana (Canagliflozin)
    • 5.1.4.2 Jardiance (Empagliflozin)
    • 5.1.4.3 Farxiga/Forxiga (Dapagliflozin)
    • 5.1.4.4 Suglat (Ipragliflozin)
    • 5.1.5 Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors
    • 5.1.5.1 Januvia (Sitagliptin)
    • 5.1.5.2 Onglyza (Saxagliptin)
    • 5.1.5.3 Tradjenta (Linagliptin)
    • 5.1.5.4 Vipidia/Nesina (Alogliptin)
    • 5.1.5.5 Galvus (Vildagliptin)
    • 5.1.6 Sulfonylureas
    • 5.1.6.1 Sulfonylureas
    • 5.1.7 Meglitinides
    • 5.1.7.1 Meglitinides
  • 5.2 Geography
    • 5.2.1 North America
    • 5.2.1.1 United States
    • 5.2.1.2 Canada
    • 5.2.1.3 Rest of North America
    • 5.2.2 Europe
    • 5.2.2.1 France
    • 5.2.2.2 Germany
    • 5.2.2.3 Italy
    • 5.2.2.4 Spain
    • 5.2.2.5 United Kingdom
    • 5.2.2.6 Russia
    • 5.2.2.7 Rest of Europe
    • 5.2.3 Latin America
    • 5.2.3.1 Mexico
    • 5.2.3.2 Brazil
    • 5.2.3.3 Rest of Latin America
    • 5.2.4 Asia-Pacific
    • 5.2.4.1 Japan
    • 5.2.4.2 South Korea
    • 5.2.4.3 China
    • 5.2.4.4 India
    • 5.2.4.5 Australia
    • 5.2.4.6 Vietnam
    • 5.2.4.7 Malaysia
    • 5.2.4.8 Indonesia
    • 5.2.4.9 Philippines
    • 5.2.4.10 Thailand
    • 5.2.4.11 Rest of Asia-Pacific
    • 5.2.5 Middle East and Africa
    • 5.2.5.1 Saudi Arabia
    • 5.2.5.2 Iran
    • 5.2.5.3 Egypt
    • 5.2.5.4 Oman
    • 5.2.5.5 South Africa
    • 5.2.5.6 Rest of Middle East and Africa

6. MARKET INDICATORS

  • 6.1 Type 1 Diabetes Population
  • 6.2 Type 2 Diabetes Population

7. COMPETITIVE LANDSCAPE

  • 7.1 Company Profiles
    • 7.1.1 Sanofi S.A.
    • 7.1.2 Eli Lilly and Company
    • 7.1.3 AstraZeneca
    • 7.1.4 Astellas Pharma Inc.
    • 7.1.5 Johnson & Johnson (Janssen Pharmaceuticals)
    • 7.1.6 Boehringer Ingelheim
    • 7.1.7 Merck And Co.
    • 7.1.8 Takeda
    • 7.1.9 Bristol Myers Squibb
    • 7.1.10 Novartis
    • 7.1.11 Pfizer
  • *List Not Exhaustive
  • 7.2 Company Share Analysis
    • 7.2.1 Sanofi S.A.
    • 7.2.2 Eli Lilly and Company
    • 7.2.3 AstraZeneca
    • 7.2.4 Merck and Co.
    • 7.2.5 Others

8. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
*The report covers a segment-wise breakdown (Value and Volume) for all the countries covered under Table of Contents **Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Oral Anti Diabetic Drugs Industry Segmentation

Oral diabetes drugs help manage blood glucose levels in patients whose bodies still produce some insulin, such as those with type 2 diabetes. These medicines are prescribed along with regular exercise and changes in the diet. The Oral Anti-Diabetic Drugs Market is segmented into drugs (Biguanides (Metformin), Alpha-glucosidase inhibitors, Dopamine-D2 receptor agonists (Bromocriptin (Cycloset)), Sodium-glucose Cotransport-2 (SGLT-2) inhibitor (Invokana (Canagliflozin), Jardiance (Empagliflozin), Farxiga/Forxiga (Dapagliflozin), and Suglat (Ipragliflozin)), Dipeptidyl Peptidase-4 (DPP-4) Inhibitors (Januvia (Sitagliptin), Onglyza (Saxagliptin), Tradjenta (Linagliptin), Vipidia/Nesina (Alogliptin), and Galvus (Vildagliptin)), Sulfonylureas, and Meglitinides), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America). The report offers the value (in USD million) and volume (in units million) for the above segments. Further, the report will cover a segment-wise breakdown (value and volume) for all the countries covered under the Table of Contents.

Drugs Biguanides Metformin
Alpha-glucosidase inhibitors Alpha-glucosidase Inhibitors
Dopamine -D2 Receptor Agonist Bromocriptin (Cycloset)
Sodium-glucose Cotransport -2 (SGLT-2) inhibitor Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors Januvia (Sitagliptin)
Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia/Nesina (Alogliptin)
Galvus (Vildagliptin)
Sulfonylureas Sulfonylureas
Meglitinides Meglitinides
Geography North America United States
Canada
Rest of North America
Europe France
Germany
Italy
Spain
United Kingdom
Russia
Rest of Europe
Latin America Mexico
Brazil
Rest of Latin America
Asia-Pacific Japan
South Korea
China
India
Australia
Vietnam
Malaysia
Indonesia
Philippines
Thailand
Rest of Asia-Pacific
Middle East and Africa Saudi Arabia
Iran
Egypt
Oman
South Africa
Rest of Middle East and Africa
Need A Different Region or Segment?
Customize Now

Oral Anti Diabetic Drugs Market Research FAQs

How big is the Oral Anti-Diabetic Drugs Market?

The Oral Anti-Diabetic Drugs Market size is expected to reach USD 48.77 billion in 2025 and grow at a CAGR of 4.17% to reach USD 59.83 billion by 2030.

What is the current Oral Anti-Diabetic Drugs Market size?

In 2025, the Oral Anti-Diabetic Drugs Market size is expected to reach USD 48.77 billion.

Who are the key players in Oral Anti-Diabetic Drugs Market?

Eli Lilly and Company, Astellas Pharma Inc., Sanofi S.A., Janssen Pharmaceuticals and AstraZeneca are the major companies operating in the Oral Anti-Diabetic Drugs Market.

Which is the fastest growing region in Oral Anti-Diabetic Drugs Market?

Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Oral Anti-Diabetic Drugs Market?

In 2025, the Asia-Pacific accounts for the largest market share in Oral Anti-Diabetic Drugs Market.

What years does this Oral Anti-Diabetic Drugs Market cover, and what was the market size in 2024?

In 2024, the Oral Anti-Diabetic Drugs Market size was estimated at USD 46.74 billion. The report covers the Oral Anti-Diabetic Drugs Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Oral Anti-Diabetic Drugs Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Oral Anti Diabetic Drugs Industry Report

Statistics for the 2025 Oral Anti-Diabetic Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Oral Anti-Diabetic Drugs analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.